Natco Pharma launches first generic version of Pomalyst capsules in the Australian Market

9 Nov 2022 , 12:00 PM

NATCO Pharma Limited has announced the launch of first generic version of Pomalyst (Pomalidomide) Capsules in 1,2,3,4 mg strengths in the Australian market. The product was launched by NATCO’s commercial partner Juno Pharmaceuticals Pty Ltd.

As per the filing, Pomalidomide is prescribed for treatment of Multiple Myeloma and Kaposi Sarcoma. For more information refer to the full prescribing information or other medical resources.

Pomalyst registered sales of USD 35.6 million in the Australian market for the year ending 31st March 2022 as per industry sales data.

At around 12:03 PM, Natco Pharma Ltd is currently trading at Rs619.40 per share down by Rs1.75 or 0.28% from its previous closing of Rs621.15 per share on the BSE.

For feedback and suggestions, write to us at [e-mail]